Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

ConditionAlopecia Areata

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age19-65

SponsorNEXTGEN Bioscience

About this trial

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Men or women between ≥19 and ≤65 years of age at the time of informed consent

Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT < 95% at Screening and Day 1/Baseline

Current episode of hair loss for ≥6 months but <8 years

Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator

Disqualifiers

ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, androgenic alopecia, telogen effluvium, etc.)

Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment

Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors

Trial design

Design model

Parallel

Treatments tested in this trial

NXC736
Drug
oral administration
Placebo
Drug
oral administration

Treatment groups

73 Participants

are divided into 2 treatment groups

Group A: NXC736Experimental treatment 1 intervention

Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

Change(%) in SALT score from baseline at Week 12

Time frame

12 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

NEXTGEN Bioscience

Lead sponsor

Source ClinicalTrials.gov

Apply now